Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Menadione

FDA-approved product (tablet, oral), marketed as Menadione.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Menadione
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vitamin k
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Menadione in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Menadione with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)

    NCT07616414 · start 2026-05-26

    Registered record
    Registry ID
    NCT07616414
    Conditions
    Non-valvular Atrial Fibrillation (NVAF); Thromboembolism; Cardiac Implantable Electronic Device; Perioperative Bleeding; Hematoma Postoperative
    Interventions
    Stepwise Anticoagulation Regimen; Standard Anticoagulation Regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-26
    Completion
    2026-12-31
    Enrolment
    424

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-valvular Atrial Fibrillation (NVAF); Thromboembolism; Cardiac Implantable Electronic Device; Perioperative Bleeding +1 more
    InterventionStepwise Anticoagulation Regimen; Standard Anticoagulation Regimen
    PhaseNot applicable
    Registry statusNot yet recruiting

  • PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

    NCT06960954 · start 2025-01-15

    Registered record
    Registry ID
    NCT06960954
    Conditions
    Hepato Cellular Carcinoma (HCC); Portal Vein Tumour Thrombosis
    Interventions
    Prothrombin induced by vitamin K absence II (PIVKA-II)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2025-12-31
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepato Cellular Carcinoma (HCC); Portal Vein Tumour Thrombosis
    InterventionProthrombin induced by vitamin K absence II (PIVKA-II)
    PhaseNot recorded
    Registry statusRecruiting

  • The Skin Anti-Aging Effects of Vitamin K2 (MK-7): a Clinical Split-Face/Neck Trial

    NCT07403942 · start 2024-12-26

    Registered record
    Registry ID
    NCT07403942
    Conditions
    Skin Aging of Face and Neck
    Interventions
    Face-and-Neck Cream (with 0.05% Vitamin K2); Placebo Face-and-Neck Cream
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-12-26
    Completion
    2025-05-19
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Aging of Face and Neck
    InterventionFace-and-Neck Cream (with 0.05% Vitamin K2); Placebo Face-and-Neck Cream
    PhaseNot applicable
    Registry statusCompleted

  • SIMPLAAFY Clinical Trial

    NCT06521463 · start 2024-10-01

    Registered record
    Registry ID
    NCT06521463
    Conditions
    Atrial Fibrillation; Stroke; Bleeding
    Interventions
    WATCHMAN FLX Pro LAAC Device
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2024-10-01
    Completion
    2027-01
    Enrolment
    1,857

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Stroke; Bleeding
    InterventionWATCHMAN FLX Pro LAAC Device
    PhaseNot applicable
    Registry statusActive not recruiting

  • An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes

    NCT05873933 · start 2024-07-01

    Registered record
    Registry ID
    NCT05873933
    Conditions
    Acne; Eczema; Skin Aging
    Interventions
    Hemptress Oil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2024-07-01
    Completion
    2024-11-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne; Eczema; Skin Aging
    InterventionHemptress Oil
    PhaseNot applicable
    Registry statusWithdrawn

  • Antioxidant and Immune Effects of Vitamin K2

    NCT05675163 · start 2022-11-15

    Registered record
    Registry ID
    NCT05675163
    Conditions
    Oxidative Stress; Inflammation
    Interventions
    Vitamin K2; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-11-15
    Completion
    2023-05-16
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOxidative Stress; Inflammation
    InterventionVitamin K2; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Vitamin K2 in the Treatment of Nocturnal Leg Cramps in Older Population

    NCT05547750 · start 2022-10-01

    Registered record
    Registry ID
    NCT05547750
    Conditions
    Nocturnal Leg Cramps
    Interventions
    Vitamin K2; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2023-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturnal Leg Cramps
    InterventionVitamin K2; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

    NCT05392127 · start 2022-07-15

    Registered record
    Registry ID
    NCT05392127
    Conditions
    Rheumatoid Arthritis
    Interventions
    SHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules; Vitamin K1 Tablets; Repaglinide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-15
    Completion
    2022-08-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionSHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules +2 more
    PhasePhase 1
    Registry statusCompleted

  • Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

    NCT05646394 · start 2022-07-01

    Registered record
    Registry ID
    NCT05646394
    Conditions
    Antiphospholipid Syndrome; Arterial Thrombosis
    Interventions
    Dual antiplatelet therapy; Combined antithrombotic therapy; Vitamin K antagonist standard intensity; Vitamin K antagonist high intensity
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-01
    Completion
    2029-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiphospholipid Syndrome; Arterial Thrombosis
    InterventionDual antiplatelet therapy; Combined antithrombotic therapy; Vitamin K antagonist standard intensity; Vitamin K antagonist high intensity
    PhaseNot recorded
    Registry statusRecruiting

  • Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

    NCT04246762 · start 2021-11-16

    Registered record
    Registry ID
    NCT04246762
    Conditions
    Rheumatoid Arthritis
    Interventions
    Olokizumab; Omeprazole; Caffeine; Warfarin+ Vitamin K; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-11-16
    Completion
    2022-10-26
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionOlokizumab; Omeprazole; Caffeine; Warfarin+ Vitamin K +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

    NCT04718740 · start 2021-06-25

    Registered record
    Registry ID
    NCT04718740
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    fluzoparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-25
    Completion
    2023-07-15
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    Interventionfluzoparib
    PhasePhase 1
    Registry statusCompleted

  • Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

    NCT04878497 · start 2021-03-30

    Registered record
    Registry ID
    NCT04878497
    Conditions
    Atrial Fibrillation; Frailty; Anticoagulant-induced Bleeding; Stroke
    Interventions
    Warfarin; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-03-30
    Completion
    2022-12-31
    Enrolment
    1,000,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Frailty; Anticoagulant-induced Bleeding; Stroke
    InterventionWarfarin; Dabigatran; Rivaroxaban; Apixaban +1 more
    PhaseNot recorded
    Registry statusUnknown

  • Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients

    NCT04145492 · start 2019-09-01

    Registered record
    Registry ID
    NCT04145492
    Conditions
    End Stage Renal Disease
    Interventions
    Vitamin K2; Cholecalciferol (inactive vitamin D); Vitamin K2 and Cholecalciferol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-09-01
    Completion
    2020-02-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease
    InterventionVitamin K2; Cholecalciferol (inactive vitamin D); Vitamin K2 and Cholecalciferol
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

    NCT03847181 · start 2019-02-28

    Registered record
    Registry ID
    NCT03847181
    Conditions
    Atrial Fibrillation
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Apixaban (Eliquis); Warfarin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-02-28
    Completion
    2020-10-31
    Enrolment
    45,164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionRivaroxaban (Xarelto, BAY59-7939); Apixaban (Eliquis); Warfarin
    PhaseNot recorded
    Registry statusCompleted

  • Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)

    NCT03813550 · start 2019-01-21

    Registered record
    Registry ID
    NCT03813550
    Conditions
    Pseudoxanthoma Elasticum
    Interventions
    Fecal and blood samples
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-21
    Completion
    2020-01-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudoxanthoma Elasticum
    InterventionFecal and blood samples
    PhaseNot applicable
    Registry statusUnknown